Physical and chemical processing for a human dura mater substitute

被引:24
作者
Dufrane, D
Cornu, O
Delloye, C
Schneider, YJ
机构
[1] Catholic Univ Louvain, Univ Tissue Bank, Orthopaed Res Lab, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Cell Biochem Lab, B-1348 Louvain, Belgium
关键词
dural substitute; human allograft; fascia lata; processing;
D O I
10.1016/S0142-9612(02)00027-3
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Object: Allogenic human fascia lata used in neurosurgery, as dura mater substitute, can be associated with a risk of viral and bacterial transmission. Chemical and physical procedures, developed to inactivate virus and bacteria, have been applied to fascia lata. The aim of this study consists in the evaluation of the biological properties of this treated graft. Methods: Grafts were treated with solvent detergents, freeze-dried for conservation and gamma irradiated (25,000 Gy) for sterilization. The indirect toxicity evaluation was performed by extraction method, according to the International Standard Organization (ISO). First, the cytotoxic effect of each extracts incubated in the presence of human fibroblasts (WI38) was quantitatively assessed by measuring the cell growth, the viability (succinate dehydrogenase activity, MTT), the membrane integrity (uptake of the neutral red by viable cells, NR) as well as the release of lactate dehydrogenase in the culture medium. Second, confocal laser scanning microscopy (CLSM) was used to assess the direct contact between human primary fibroblasts and graft. CLSM was performed at days 3 and 7 after cells loading. Results: No acute cytotoxicity was observed for chemically processed allografts. Cells loaded on the graft have demonstrated a good growth and spreading. Conclusions: Human fascia lata secured against conventional and non-conventional agents is a fully biocompatible alternative to the available dural graft materials. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:2979 / 2988
页数:10
相关论文
共 54 条
  • [1] Ethanol treatment of tendon allografts: a potential HIV inactivating procedure
    Anastasescou, M
    Cornu, O
    Banse, X
    Konig, J
    Hassoun, A
    Delloye, C
    [J]. INTERNATIONAL ORTHOPAEDICS, 1998, 22 (04) : 252 - 254
  • [2] BACALLAO R, 1989, METHOD CELL BIOL, V31, P437
  • [3] CHEMICAL DISINFECTION OF CREUTZFELDT-JAKOB DISEASE VIRUS
    BROWN, P
    GIBBS, CJ
    AMYX, HL
    KINGSBURY, DT
    ROHWER, RG
    SULIMA, MP
    GAJDUSEK, DC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (21) : 1279 - 1282
  • [4] BROWN P, 1984, NEW ENGL J MED, V310, P727
  • [5] BUCK BE, 1989, CLIN ORTHOP RELAT R, V240, P129
  • [6] CAMPBELL DG, 1994, INT ORTHOP, V18, P172
  • [7] Bone allograft banking in South Australia
    Campbell, DG
    Oakeshott, RD
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1995, 65 (12): : 865 - 869
  • [8] A comparative study of the use of colorimetric assays in the assessment of biocompatibility
    Clifford, CJ
    Downes, S
    [J]. JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 1996, 7 (10) : 637 - 643
  • [9] TRANSMISSION OF THE HEPATITIS-C VIRUS BY TISSUE-TRANSPLANTATION
    CONRAD, EU
    GRETCH, DR
    OBERMEYER, KR
    MOOGK, MS
    SAYERS, M
    WILSON, JJ
    STRONG, M
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1995, 77A (02) : 214 - 224
  • [10] RADIOSENSITIVITY OF HIV-1 - POTENTIAL APPLICATION TO STERILIZATION OF BONE ALLOGRAFTS
    CONWAY, B
    TOMFORD, W
    MANKIN, HJ
    HIRSCH, MS
    SCHOOLEY, RT
    [J]. AIDS, 1991, 5 (05) : 608 - 609